Study of the Effects of Glycine on Symptoms and Memory in Patients With Schizophrenia
NCT00575848 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16
Last updated 2009-11-26
Summary
The goal of this project is to understand whether glycine is helpful for improving some symptoms of schizophrenia such as low motivation, loss of interest, and social isolation. In addition, the investigators want to find out if glycine improves memory.
This project involves a three-and-a-half month trial of glycine or placebo. A placebo looks exactly like the study drug, but it contains no active drug. Glycine is a naturally occurring substance that is a part of some of the proteins in your body. Glycine has not been approved by the FDA (Food and Drug Administration) for the treatment of schizophrenia. However, the FDA allows it to be used in research studies.
Related Study at McLean Hospital: If you would like to participate in this study of glycine versus placebo at the Freedom Trail Clinic, the investigators will ask you if you would also like to participate in a related study at McLean Hospital. The study at McLean Hospital will look at the effects of glycine and placebo on levels of glycine in the brain. The study will use magnetic resonance spectroscopy to measure brain glycine levels. The magnetic resonance (MR) scanner looks like a large cylinder with a tube running down the center. You will be asked to lie down on your back on a foam-padded table and place your head into a special holder. The table will slide you inside the "hole" of the scanner. Soft foam rubber sponges may be placed on both sides of your head for comfort and to help keep your head from moving. Because the scanner contains a strong magnet, you will be asked to remove all metal objects from your person including, but not limited to: watches, rings, necklaces, bracelets, earrings and other body piercings, belts, loose change, wallet (with credit cards), items of clothing containing magnetic materials (for example, underwire bras, certain types of zippers), and shoes. These items will be secured in a safe place until your scan is completed. You will be able to remain in your street clothes. The investigators will ask you if study staff from McLean Hospital can contact you to tell you more about the study. You may refuse to be contacted by McLean Hospital. However, if you do not participate in the study at McLean, you are not eligible for the study here at the Freedom Trail Clinic.
Conditions
- Schizophrenia
- Schizoaffective Disorder
Interventions
- DIETARY_SUPPLEMENT
-
Glycine
Subjects will consume glycine twice daily, once with breakfast and once with dinner. The medication is in liquid form. They will be instructed to refrigerate the liquid until the time that they take it. Subjects start by taking 10g per day for the first 2 days. Starting on the 3rd day, subjects take 0.2g/kg (15g for a 75kg adult) per day, and increase dosage by 0.2g/kg every two days, until they reach 0.8g/kg per day, which they take for the remainder of the 6-week period.
- DIETARY_SUPPLEMENT
-
Placebo
Subjects will consume placebo twice daily, once with breakfast and once with dinner. The placebo is in liquid form. They will be instructed to refrigerate the liquid until the time that they take it. Subjects start by taking 10g per day for the first 2 days. Starting on the 3rd day, subjects take 0.2g/kg (15g for a 75kg adult) per day, and increase dosage by 0.2g/kg every two days, until they reach 0.8g/kg per day, which they take for the remainder of the 6-week period.
Sponsors & Collaborators
-
Mclean Hospital
collaborator OTHER -
National Alliance for Research on Schizophrenia and Depression
collaborator OTHER -
North Suffolk Mental Health Association
lead OTHER
Principal Investigators
-
A. Eden Evins, M.D., M.P.H. · Massachusetts General Hospital
-
Andrew Prescot, Ph.D. · Mclean Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- DOUBLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-12-31
- Primary Completion
- 2008-10-31
- Completion
- 2008-10-31
Countries
- United States
Study Locations
More Related Trials
-
A Study of the Effects of Sarcosine on Symptoms and Brain Glycine Levels in People With Schizophrenia
NCT00538070 ·Status: COMPLETED ·Phase: NA
-
Glycine to Treat Psychotic Disorders in Children
NCT00005658 ·Status: COMPLETED ·Phase: PHASE2
-
Adjunctive Treatment for Decreasing Symptoms of Schizophrenia
NCT00222235 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in Schizophrenia
NCT01232790 ·Status: COMPLETED ·Phase: NA
-
Translational Neuroscience Optimization of GlyT1 Inhibitor
NCT01911676 ·Status: COMPLETED ·Phase: PHASE2
-
Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia
NCT00728728 ·Status: COMPLETED ·Phase: PHASE2
-
Effectiveness of Vitamin Supplementation in Treating People With Residual Symptoms of Schizophrenia
NCT00611806 ·Status: COMPLETED ·Phase: PHASE4
-
A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis
NCT00591318 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
NRX-1074 in Early Course Schizophrenia
NCT02603458 ·Status: WITHDRAWN ·Phase: PHASE2
-
Treatment of N-methyl-D-aspartate (NMDA) Enhancers for Schizophrenia
NCT01047592 ·Status: COMPLETED ·Phase: PHASE2
-
Adjuvant Treatment With a Glycine Uptake Inhibitor in Participants With Negative Symptoms of Schizophrenia (P05695) (MK-8435-001)
NCT00725075 ·Status: COMPLETED ·Phase: PHASE2
-
D-serine for the Schizophrenia Prodrome
NCT00826202 ·Status: COMPLETED ·Phase: PHASE2
-
Ketogenic Diet in People With Schizophrenia
NCT05968638 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
GlyT-1 Inhibitor Treatment for Refractory Schizophrenia
NCT01251055 ·Status: COMPLETED ·Phase: PHASE2
-
Trial of D-Cycloserine in Schizophrenia
NCT00000371 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Nicotine Transdermal Patch on Cognitive Function and Glycolipid Metabolism in Non-smoking Schizophrenia
NCT05301660 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) Antagonism
NCT02675530 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine
NCT02505477 ·Status: COMPLETED ·Phase: PHASE4
-
Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study
NCT00129441 ·Status: COMPLETED ·Phase: PHASE2
-
Sulforaphane to Reduce Symptoms of Schizophrenia
NCT02810964 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia
NCT00455702 ·Status: COMPLETED ·Phase: PHASE4
-
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
NCT00570063 ·Status: TERMINATED ·Phase: PHASE2
-
The Effect of Plasma Osmolality on Brain Glutamate
NCT00611741 ·Status: COMPLETED ·Phase: PHASE1
-
Biomarker Study of Acamprosate in Schizophrenia
NCT00688324 ·Status: COMPLETED ·Phase: PHASE4
-
Confirmatory Efficacy Trial of a Gluten-Free Diet in a Subgroup of Persons With Schizophrenia Who Have High Levels of IgG Anti-Gliadin Antibodies (AGA IG)
NCT03183609 ·Status: COMPLETED ·Phase: NA